Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Ginkgo Bioworks Holdings, Inc. Stock Research

DNA

1.74USD+0.03(+1.75%)Delayedas of 03 Oct 2023, 09:56 am
Watchlist

Market Summary

USD1.74+0.03
Delayedas of 03 Oct 2023, 09:56 am
1.75%

DNA Alerts

  • 1 major insider sales recently.
  • Big fall in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

DNA Stock Price

DNA RSI Chart

DNA Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

-2.7

Price/Sales (Trailing)

10.14

EV/EBITDA

-1.92

Price/Free Cashflow

-8.96

DNA Price/Sales (Trailing)

DNA Profitability

EBT Margin

-444.49%

Return on Equity

-106.95%

Return on Assets

-71.13%

Free Cashflow Yield

-11.16%

DNA Fundamentals

DNA Revenue

Revenue (TTM)

326.0M

Revenue Y/Y

-44.29%

Revenue Q/Q

-0.17%

DNA Earnings

Earnings (TTM)

-1.2B

Earnings Y/Y

74.09%

Earnings Q/Q

15.44%

Price Action

52 Week Range

1.123.52
(Low)(High)

Last 7 days

-1.2%

Last 30 days

-24%

Last 90 days

-3.9%

Trailing 12 Months

-45.2%

DNA Financial Health

Current Ratio

6.92

DNA Investor Care

Shares Dilution (1Y)

19.30%

Diluted EPS (TTM)

-0.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for DNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-28
Kelly Jason R
sold
-174,900
1.749
-100,000
see remarks
2023-09-28
Canton Barry
sold
-65,887
1.75
-37,650
-
2023-09-28
Shetty Reshma P.
sold
-65,887
1.75
-37,650
see remarks
2023-09-27
Shetty Reshma P.
sold
-68,899
1.83
-37,650
see remarks
2023-09-27
Canton Barry
sold
-68,899
1.83
-37,650
-
2023-09-27
Kelly Jason R
sold
-182,500
1.825
-100,000
see remarks
2023-09-21
Kelly Jason R
sold
-176,600
1.766
-100,000
see remarks
2023-09-21
Canton Barry
sold
-66,452
1.765
-37,650
-
2023-09-21
Shetty Reshma P.
sold
-66,452
1.765
-37,650
see remarks
2023-09-20
Shetty Reshma P.
sold
-69,238
1.839
-37,650
see remarks

1–10 of 50

Which funds bought or sold DNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
new
-
21,604
21,604
-%
2023-09-20
BARCLAYS PLC
reduced
-55.97
-401,000
644,000
-%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
new
-
1,860
1,860
-%
2023-08-23
WOLVERINE TRADING, LLC
added
151
56,767
77,767
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
26.51
1,087,050
2,500,150
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
4.41
175,770
556,647
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-15.52
54.00
286
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
486,000
1,703,000
0.02%
2023-08-17
Coastal Bridge Advisors, LLC
new
-
669,600
669,600
0.16%
2023-08-17
Coastal Bridge Advisors, LLC
unchanged
-
888
2,832
-%

1–10 of 45

Latest Funds Activity

Are funds buying DNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DNA
No. of Funds

Schedule 13G FIlings of Ginkgo Bioworks Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
che austin
6.3%
99,857,282
SC 13G/A
Feb 14, 2023
knight thomas f. jr.
5.0%
74,936,116
SC 13G/A
Feb 14, 2023
anchorage capital group, l.l.c.
4.83%
69,904,593
SC 13G/A
Feb 14, 2023
viking global investors lp
9.36%
143,085,126
SC 13G/A
Feb 13, 2023
general atlantic, l.p.
2.4%
32,319,896
SC 13G/A
Feb 09, 2023
vanguard group inc
7.49%
101,521,280
SC 13G
Jan 25, 2023
shetty reshma p.
12.0%
195,788,523
SC 13D/A
Jan 25, 2023
kelly jason r
6.2%
97,017,435
SC 13D/A
Jan 23, 2023
baillie gifford & co
18.03%
244,176,643
SC 13G/A
Jul 01, 2022
viking global investors lp
9.7%
115,084,128
SC 13G

Recent SEC filings of Ginkgo Bioworks Holdings

View All Filings
Date Filed Form Type Document
Oct 02, 2023
144
Notice of Insider Sale Intent
Oct 02, 2023
144
Notice of Insider Sale Intent
Oct 02, 2023
144
Notice of Insider Sale Intent
Sep 29, 2023
4
Insider Trading
Sep 29, 2023
4
Insider Trading
Sep 29, 2023
4
Insider Trading
Sep 29, 2023
144
Notice of Insider Sale Intent
Sep 28, 2023
144
Notice of Insider Sale Intent
Sep 28, 2023
144
Notice of Insider Sale Intent
Sep 28, 2023
144
Notice of Insider Sale Intent

Ginkgo Bioworks Holdings News

InvestorsObserver
Ginkgo Bioworks Holdings Inc (DNA) Up 1.17% in Premarket Trading.
InvestorsObserver,
2 hours ago
InvestorsObserver
Stockhouse Publishing
InvestorsObserver

Returns for DNA

Cumulative Returns on DNA

Risks for DNA

What is the probability of a big loss on DNA?

75.2%


Probability that Ginkgo Bioworks Holdings stock will be more than 20% underwater in next one year

75.2%


Probability that Ginkgo Bioworks Holdings stock will be more than 30% underwater in next one year.

72.1%


Probability that Ginkgo Bioworks Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ginkgo Bioworks Holdings was unfortunately bought at previous high price.

Drawdowns

Financials for Ginkgo Bioworks Holdings

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Revenue-16.4%325,953,000390,003,000477,706,000527,915,000539,127,000438,145,000313,837,000197,401,000133,093,000119,276,00076,657,00053,208,00054,184,000
Operating Expenses-24.6%1,613,378,0002,141,056,0002,686,658,0004,188,821,0003,573,684,0002,884,868,0002,142,304,000397,021,000340,454,000315,830,667213,684,000190,860,000125,782,000
  S&GA Expenses-50.1%446,925,333895,040,0001,429,799,000-1,665,349,333-862,952,00062,521,333-37,077,33319,762,00039,504,00029,483,000
  R&D Expenses-16.3%747,656,000893,433,0001,052,643,0001,858,240,0001,651,681,0001,413,653,0001,149,662,000225,828,000208,877,000209,128,000159,767,000144,280,00096,299,000
EBITDA100.0%--1,665,891,000-2,078,741,000-3,490,597,000-3,033,922,000-2,220,765,145-1,818,701,000-135,043,545-145,464,211-62,942,200-98,777,000-58,161,333-157,317,000
EBITDA Margin100.0%--4.27-4.35-6.61-5.63-5.07-5.80-0.68-1.09-0.82-1.29-1.09-2.90
Interest Expenses77.3%27,723,00015,638,000106,00011,761,0005,413,0002,671,0002,373,000-1,792,0007,029,00010,009,3332,385,00033,172,0002,421,000
Earnings Before Taxes28.7%-1,236,142,000-1,733,509,000-2,121,399,000-3,538,153,000-2,971,682,000-2,355,962,000-1,838,122,000-278,835,000-202,343,000-196,597,333-124,834,000-104,480,000-119,835,000
EBT Margin100.0%--4.44-4.44-6.70-5.51-5.50-5.86-1.27-1.30-1.16-1.63-1.96-2.21
Net Income28.8%-1,223,883,000-1,719,393,000-2,104,929,000-3,529,041,000-2,961,867,000-2,346,983,000-1,830,047,000-229,396,000-153,570,000-128,359,000-80,258,000-107,004,000-119,327,000
Net Income Margin100.0%--4.41-4.41-6.68-5.49-5.48-5.83-1.03-0.95-0.64-1.05-2.01-2.20
Free Cashflow100.0%--391,017,000-304,469,000-344,778,000-313,676,000-311,411,562-310,339,000-159,097,000-197,898,666-58,761,876-57,821,000-153,198,666-66,882,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42019Q4
Assets-5.2%2,2922,4172,5391,8711,9942,0582,0712,1511,7261,728675697
  Current Assets-7.8%1,2231,3271,4501,4621,5991,7061,7231,8111.003.00427512
    Cash Equivalents-8.3%1,1061,2061,3161,3031,3771,4931,5501,739236308381495
  Inventory-84.4%0.003.004.006.008.009.003.003.00--3.00-
  Net PPE-6.3%294314315188176149146143--12163.00
  Goodwill0.2%59.0059.0060.0029.0031.0021.0021.0017.00--2.002.00
Liabilities-2.6%788810803431427444504533255150205195
  Current Liabilities-14.8%16319217312513515913590.005.001.0073.0040.00
Shareholder's Equity-6.5%1,5041,6081,7361,4351,5721,6191,5671,618356396470502
  Retained Earnings-3.8%-4,775-4,602-4,397-4,226-3,557-2,888-2,297-697-1015.00-467-341
  Additional Paid-In Capital1.1%6,2816,2126,1365,6695,0984,4713,8052,250106-929-
Shares Outstanding-1,933--1,6311,6211,6071,6111,3241,2931,2901,2891,256
Minority Interest----5.0032.0033.0062.0066.00--9.009.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Cashflow From Operations8.0%-297-322-252-313-290-225-253-88.28-110-96.26--101-44.66
  Share Based Compensation-40.3%8061,3511,9313,4142,8512,2591,60615.0020.000.000.000.001.00
Cashflow From Investing6.8%-47.38-50.82-67.39-92.91-76.93-86.20-73.26-106-101-103-67.12-51.05-74.60
Cashflow From Financing-0.6%95.0096.0095.00-13.641,5351,5331,5341,545-3.66-1.2490.00121410
  Buy Backs-------25.00100----0.00

DNA Income Statement

2023-06-30
Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
[1]
Biosecurity revenue:    
Total Revenue$ 80,568$ 144,618$ 161,270$ 313,023
Costs and operating expenses:    
Research and development144,282290,059306,921613,635
General and administrative102,341438,427213,774873,195
Total operating expenses264,719792,397561,1661,636,173
Loss from operations(184,151)(647,779)(399,896)(1,323,150)
Other income (expense):    
Interest income, net14,3492,26428,8942,441
Loss on equity method investments(67)(10,166)(1,516)(31,053)
Loss on investments(2,121)(38,673)(8,491)(38,223)
Change in fair value of warrant liabilities(4,482)23,509(3,278)108,544
Gain on deconsolidation of subsidiary00015,900
Other income, net3,2242306,1522,149
Total other income (expense), net10,903(22,836)21,76159,758
Loss before income taxes(173,248)(670,615)(378,135)(1,263,392)
Income tax expense (benefit)67(45)149(229)
Net loss(173,315)(670,570)(378,284)(1,263,163)
Loss attributable to non-controlling interest0(1,745)0(3,833)
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders$ (173,315)$ (668,825)$ (378,284)$ (1,259,330)
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders:    
Basic$ (0.09)$ (0.41)$ (0.2)$ (0.78)
Diluted$ (0.09)$ (0.41)$ (0.2)$ (0.78)
Weighted average common shares outstanding    
Basic1,933,4371,620,7041,924,2511,614,138
Diluted1,933,4371,620,7041,924,2511,614,138
Comprehensive loss:    
Net loss$ (173,315)$ (670,570)$ (378,284)$ (1,263,163)
Other comprehensive income (loss):    
Foreign currency translation adjustment314(3,141)1,332(3,781)
Total other comprehensive income (loss)314(3,141)1,332(3,781)
Comprehensive loss(173,001)(673,711)(376,952)(1,266,944)
Product [Member]    
Biosecurity revenue:    
Total Revenue10,7883,88722,45417,834
Costs and operating expenses:    
Cost of Biosecurity revenue2,0342,4446,57510,539
Service [Member]    
Biosecurity revenue:    
Total Revenue24,49796,48959,437229,459
Costs and operating expenses:    
Cost of Biosecurity revenue16,06261,46733,896138,804
Cell Engineering revenue [Member]    
Biosecurity revenue:    
Total Revenue[2]$ 45,283$ 44,242$ 79,379$ 65,730
[1]As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.
[2]Includes related party revenue of $6,507 and $7,973 for the three months ended June 30, 2023 and 2022, respectively, and $11,212 and $21,501 for the six months ended June 30, 2023 and 2022, respectively.

DNA Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,105,787$ 1,315,792
Accounts receivable, net68,01980,907
Accounts receivable - related parties8991,558
Inventory, net3914,364
Prepaid expenses and other current assets48,35747,458
Total current assets1,223,4531,450,079
Property, plant, and equipment, net294,244314,773
Operating lease right-of-use assets391,430400,762
Investments119,944112,188
Equity method investments1,1201,543
Intangible assets, net105,033111,041
Goodwill58,82960,210
Other non-current assets97,94688,725
Total Assets2,291,9992,539,321
Current liabilities:  
Accounts payable13,63010,451
Deferred revenue (includes $6,473 and $10,309 from related parties)39,22347,817
Accrued expenses and other current liabilities110,478114,694
Total current liabilities163,331172,962
Non-current liabilities:  
Deferred revenue, net of current portion (includes $132,799 and $131,188 from related parties)179,903174,767
Operating lease liabilities, non-current410,938413,256
Warrant liabilities14,14610,868
Other non-current liabilities20,09631,191
Total Liabilities788,414803,044
Commitments and contingencies (Note 7)
Shareholders' equity:  
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued00
Common stock, $0.0001 par value (Note 6)196190
Additional paid-in capital6,280,6326,136,378
Accumulated deficit(4,775,943)(4,397,659)
Accumulated other comprehensive loss(1,300)(2,632)
Total stockholders equity1,503,5851,736,277
Total Liabilities and Shareholders' Equity$ 2,291,999$ 2,539,321
Jason Kelly
640
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.